Paper Details

  1. Home
  2. Paper Details

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.

Author: AounMickael, BaddleyJohn W, BowEric J, CornelyOliver A, GiladiMichael, HeinzWerner J, HerbrechtRaoul, HopeWilliam, KarthausMeinolf, KontoyiannisDimitrios P, LeeDong-Gun, LeeMisun, LortholaryOlivier, MaertensJohan A, MaherRochelle M, MarrKieren A, MorrisonVicki A, NeofytosDionysios, OrenIlana, PattersonThomas F, RaadIssam I, RahavGalia, Schmitt-HoffmannAnne-Hortense, SelleslagDominik, ShohamShmuel, ThompsonGeorge R, UllmannAndrew J, ZeiherBernhardt

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Isavuconazole was found to be non-inferior to voriconazole for the primary treatment of suspected invasive mould disease, and was well tolerated.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Isavuconazole is a novel triazole with broad-spectrum antifungal activity. The SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients with invasive mould disease. METHODS: This was a phase 3, double-blind, global multicentre, comparative-group study. ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0140-6736(15)01159-9

データ提供：米国国立医学図書館（NLM）

A New Weapon in the Fight Against Invasive Mould Disease

Invasive mould disease, a serious and potentially life-threatening infection, poses a significant challenge to healthcare professionals. This phase 3 randomized controlled trial evaluates the efficacy and safety of isavuconazole, a novel antifungal agent, compared to voriconazole, a standard treatment option, in patients with suspected invasive mould disease. The study aims to assess the effectiveness of isavuconazole in battling this formidable foe.

A Battle of Antifungals

The study found that isavuconazole was non-inferior to voriconazole in terms of all-cause mortality, a critical endpoint in the fight against invasive mould disease. This indicates that isavuconazole offers a comparable level of effectiveness to the established standard of care. Moreover, isavuconazole was well-tolerated, with fewer study-drug-related adverse events compared to voriconazole. This suggests that isavuconazole may offer a valuable alternative for patients with invasive mould disease, potentially providing similar efficacy with a better safety profile.

New Hope on the Horizon

This study offers promising news in the fight against invasive mould disease. The development of new antifungal agents, like isavuconazole, provides healthcare providers with additional tools to combat this serious infection. The findings suggest that isavuconazole may be a valuable addition to the therapeutic arsenal, offering potential benefits in both efficacy and safety. As we continue to explore new avenues for treating invasive mould disease, this study provides a ray of hope, illuminating a path towards improved outcomes for patients facing this challenging infection.

Dr. Camel's Conclusion

Invasive mould disease is a formidable foe, like a sandstorm that can quickly engulf the desert. This study offers a beacon of hope, illuminating the potential of isavuconazole, a new weapon in the fight against this serious infection. With its comparable efficacy and improved safety profile, isavuconazole may offer a vital tool for navigating the challenges of invasive mould disease and improving outcomes for patients facing this daunting challenge.

Date :
  1. Date Completed 2016-03-07
  2. Date Revised 2022-03-16
Further Info :

Pubmed ID

26684607

DOI: Digital Object Identifier

10.1016/S0140-6736(15)01159-9

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.